Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue: +4.13%
EPS: −21.7%
Free cash flow: −63.7%

Quarter to September 2026, against a year earlier

565.63 0.09 −0.02%

Follow UTHR

Alert me

Market cap: $24.3B
P/E: 19.7×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 8/9
Altman Z: 19.55
Beneish M: −2.26
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

United Therapeutics Corporation (UTHR) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, United Therapeutics Corporation (UTHR) trades at a P/B ratio of 3.8×. Over the past ten years it has ranged from 1.3× (March 2020) to 8.1× (April 2015); the current reading is higher than 88% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/UTHR/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="United Therapeutics Corporation P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/UTHR/metrics/pb-ratio">United Therapeutics Corporation (UTHR) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	3.0×	22.91%
FY2024	2.5×	39.21%
FY2023	1.8×	(31.43%)
FY2022	2.6×	5.79%
FY2021	2.5×	24.02%
FY2020	2.0×	42.42%
FY2019	1.4×	(18.32%)
FY2018	1.7×	(46.59%)
FY2017	3.2×	(6.63%)
FY2016	3.4×	(24.88%)

Period	P/B ratio	Change
Sep 2026	3.6×	0.25%
Jun 2026	3.6×	(17.50%)
Mar 2026	4.4×	43.70%
Dec 2025	3.0×	9.17%
43 more quarters	Free account

Against its own ten years

Low 1.3× High 8.1×

Ten-year median 2.4×

Current reading's percentile 96

Company	P/B ratio
TAK Takeda Pharmaceutical Co. compare	1.4×
VTRS Viatris Inc. compare	1.6×
ELAN Elanco Animal Health Incorporated compare	1.8×
HLN Haleon PLC Sponsored ADR compare	1.9×
RDY Dr. Reddy's Laboratories Ltd compare	3.0×
UTHR United Therapeutics Corporation	3.8×
NBIX Neurocrine Biosciences, Inc. compare	4.2×
TEVA Teva Pharmaceutical Industries Ltd. compare	6.1×
ZTS Zoetis Inc. compare	10.8×
Drug Manufacturers Specialty & Generic industry median	1.8×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

United Therapeutics Corporation (UTHR) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on UTHR

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on UTHR

Stockrow Weekly